The aim of the present study was to investigate the clinical significance of conventional and new markers (HJURP, HIF-1α, and TG2) in in situ breast cancer and in the tumor microenvironment and to assess any correlation with clinical outcome in patients homogeneously treated with surgery and postsurgery radiation therapy. The gene discussed is HIF1A; the disease is neoplasm.